This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

This week we've had EyesOn all the recent Business Development activities in the BioPharma world. We're sharing a few that caught our eye. Check out AbbVie's acquisition of Apogee to strengthen out their I&I portfolio, Sangamo's asset sale, and Pfizer's recent clinical results from one of their Seagen candidates.

From workforce reductions to manufacturing bottlenecks and regulatory divergence, structural pressures are reshaping how pharma operates.

Korsana Biosciences raised $175 million to develop next-generation Alzheimer’s antibodies. Its lead candidate uses transferrin receptor targeting to cross the blood-brain barrier. The company plans to enter clinical trials in 2027. Several competitors are pursuing similar delivery strategies.

The week we've had Eyes on the Ocular Therapeutix phase 3 SOL-1 data showing superiority over Eylea in wet AMD. The trial showed improved visual acuity preservation, The program could introduce the first tyrosine kinase inhibitor therapy for wet AMD however, investors reacted cautiously to the news.

This week we had Eyes On recent FDA actions including the approval of AstraZeneca’s first fixed-duration BTK inhibitor regimen for first-line CLL/SLL; A warning letter for Johnson & Johnson concerning promotional claims for Tremfya; and Moderna's resolution of the refusal-to-file dispute and a PDUFA for it's flu vaccine decision in 2026.

AstraZeneca doubles down on $80B target amid catalyst-rich 2026 pipeline. With more than 100 phase 3 trials underway with 20+ readouts expected this year, the company faces both blockbuster opportunity and Farxiga's patent cliff risk.